Literature DB >> 11106072

The expression of cyclins D1 and E in predicting short-term survival in squamous cell carcinoma of the lung.

R C Anton1, D M Coffey, M M Gondo, M A Stephenson, R W Brown, P T Cagle.   

Abstract

Cyclins D1 (cD1) and E (cE) are G1 phase cyclins believed to participate in the pathogenesis of malignancy. Overexpression of cD1 has been reported to influence prognosis in squamous cell carcinomas (SCC) of the larynx, but was not significant in a limited study of non-small cell lung cancers (NSCLC). Altered expression of cE has been proposed as another potential prognostic marker in malignancy but its possible role in NSCLC has not been elucidated. In order to determine the prognostic value of cD1 and cE in NSCLC, paraffin-embedded sections of 467 NSCLC were immunostained with monoclonal antibody to cD1 (1:500, PharMingen, San Diego, CA) and 400 NSCLC with MA to cE (1:2500, PharMingen) using an enhanced sensitivity avidin-biotin complex technique. The number of tumor cells with nuclear and/or cytoplasmic immunopositivity was graded on a scale of: 0 = less than 1%, 1 = 1 to 10%, 2 = 10 to 25%, 3 = 25 to 50%, 4 = 50 to 75%, 5 = more than 75%. Results were correlated with survival by Kaplan-Meier survival plot using Stat-View software (Abacus Concepts, Berkeley, CA). Overall, 426 NSCLC with cD1 and 360 NSCLC with cE had adequate follow-up (median, 76 mo) for survival analysis. Both cyclins independently showed significance in prognosis of SCC but not other cell types. For cD1, absence of immunostaining was associated with worse prognosis than any immunopositivity for all stages of SCC (P = .025). For cE, Stage I and II SCC with less than 50% immunopositivity had a worse prognosis (P = .029). Of 70 Stage I and II SCC immunostained for both monoclonal antibodies, 55% of patients with tumors that demonstrated both absence of cD1 staining and cE immunopositivity in less than 50% of cells were dead at 5 years compared to 35% of patients with tumors that demonstrated positive staining with cD1 and cE immunopositivity in more than 50% of cells. These results strongly suggest cD1 and cE can independently predict prognosis in early stage SCC. Worse prognosis was associated with loss of expression, consistent with mechanisms other than overexpression of these cyclins in the progression of SCC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106072     DOI: 10.1038/modpathol.3880215

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  7 in total

1.  Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.

Authors:  Wusheng Yan; Ignacio I Wistuba; Michael R Emmert-Buck; Heidi S Erickson
Journal:  Am J Cancer Res       Date:  2011-01-01       Impact factor: 6.166

Review 2.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.

Authors:  C-Q Zhu; W Shih; C-H Ling; M-S Tsao
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

3.  Prognostic value of cyclin D1 overexpression in correlation with pRb and p53 status in non-small cell lung cancer (NSCLC).

Authors:  Dorota Dworakowska; Ewa Jassem; Jacek Jassem; Carsten Boltze; Klaus Hermann Wiedorn; Rafał Dworakowski; Jan Skokowski; Kazimierz Jaśkiewicz; Eugenia Czestochowska
Journal:  J Cancer Res Clin Oncol       Date:  2005-04-05       Impact factor: 4.553

Review 4.  Prognostic markers in lung cancer: is it ready for prime time?

Authors:  Chang-Qi Zhu; Ming-Sound Tsao
Journal:  Transl Lung Cancer Res       Date:  2014-06

5.  A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle.

Authors:  Ezra E W Cohen; Hongyan Zhu; Mark W Lingen; Leslie E Martin; Wen-Liang Kuo; Eugene A Choi; Masha Kocherginsky; Joel S Parker; Christine H Chung; Marsha Rich Rosner
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

Review 6.  Review of MicroRNA Proposed Target Genes in Oral Cancer. Part II.

Authors:  Antonia Kolokythas; Michael Miloro; Xiaofeng Zhou
Journal:  J Oral Maxillofac Res       Date:  2011-07-01

7.  Cyclin D1, cyclin E, and p21 have no apparent prognostic value in anal carcinomas treated by radiotherapy with or without chemotherapy.

Authors:  A S Allal; P Gervaz; M-A Bründler
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.